Cervical cancer screening among women living with HIV
Proportion of women living with HIV screened for cervical cancer
With an estimated 570 000 cases and 311 000 deaths worldwide in 2018, cervical cancer ranks as the fourth most frequently diagnosed cancer and the fourth leading cause of cancer deaths among women. It is the second most common type of cancer among women living in low- and middle-income countries.
In high-income countries, programmes are in place that enable women to get screened, making most precancerous lesions identifiable at stages when they can easily be treated and cured. Achieving high coverage of screening of women - and treatment of precancerous lesions detected by screening - can ensure a low incidence of invasive cervical cancer in high-income countries.
Women living with HIV are more vulnerable than HIV-negative women to being affected by cervical cancer and to developing invasive cancer. Invasive cervical cancer is an AIDS-defining condition and the most common cancer among women living with HIV. Compared to women not living with HIV, women living with HIV are up to five times more likely to develop invasive cervical cancer. For these reasons, screening women living with HIV is important. This can prevent up to 80% of the cases of cervical cancer in these countries.
Number of women living with HIV who report ever having had a screening test for cervical cancer using any of these methods: VIA, Pap smear and HPV test.
All women respondents living with HIV
- Nationally representative population-based surveys
- Programmatic data: If you do not have the number of women living with HIV (aged 30–49 years) who have ever been screened for cervical cancer, you also can provide the number of women who tested positive for HIV among all women who were screened for cervical cancer.
Data should be collected at least every five years
- Age (15-29, 30–49).
- Tested in the last year.
Potential limitations include bias through self-report, including mistakenly assuming that any pelvic exam was a test for cervical cancer, and the limited validity of survey instruments.